Last reviewed · How we verify
doxorubicine + cyclophosphamide combined
Doxorubicin is a topoisomerase II inhibitor that intercalates DNA, while cyclophosphamide is an alkylating agent that cross-links DNA.
Doxorubicin is a topoisomerase II inhibitor that intercalates DNA, while cyclophosphamide is an alkylating agent that cross-links DNA. Used for Breast cancer, Lymphoma.
At a glance
| Generic name | doxorubicine + cyclophosphamide combined |
|---|---|
| Sponsor | Sanofi |
| Drug class | anthracycline + alkylating agent |
| Target | topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Doxorubicin works by inhibiting the enzyme topoisomerase II, which is necessary for DNA replication and transcription. This leads to DNA damage and ultimately cell death. Cyclophosphamide, on the other hand, is an alkylating agent that adds an alkyl group to DNA, causing cross-links and DNA damage, which also leads to cell death.
Approved indications
- Breast cancer
- Lymphoma
Common side effects
- Myelosuppression
- Cardiotoxicity
- Nausea and vomiting
- Hair loss
- Fatigue
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (PHASE1)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- doxorubicine + cyclophosphamide combined CI brief — competitive landscape report
- doxorubicine + cyclophosphamide combined updates RSS · CI watch RSS
- Sanofi portfolio CI